<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396227</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A23119</org_study_id>
    <nct_id>NCT00396227</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone</brief_title>
  <official_title>A Multi-center, Randomized, Open-label, Active Controlled, Parallel Arm Study to Compare the Efficacy of 12 Weeks of Treatment With Vildagliptin 100 mg, qd to Thiazolidinedione (TZD) as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in a Community-based Practice Setting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate, in a primary care setting, the safety and efficacy of
      vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients
      with type 2 diabetes inadequately controlled by metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HemoglobinA1c (HbA1c)</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body weight</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (FPG)</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of prespecified adverse events while on treatment with study drug</measure>
    <time_frame>12 week treatment duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2665</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin 100mg + Met</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TZD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TZD + metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <description>vildagliptin as add-on to metformin</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiazolidinedione (TZD)</intervention_name>
    <description>TZD add-on to metformin</description>
    <arm_group_label>TZD</arm_group_label>
    <other_name>Actos (pioglitazone), Avandia (rosiglitazone)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have received a stable dose of metformin consisting of at least 1,000
             mg/day for four weeks prior to Visit 1 (week-2)

          -  Agreement to maintain the same dose of metformin from screening to the end of the
             study

          -  Age in the range of 18-80 years

          -  Body mass index (BMI) in the range of 22-40 kg/m2

          -  HbA1c in the range of 7.0 to 10%

          -  FPG &lt;270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  A history of type 1 diabetes

          -  Liver disease

          -  Treatment with insulin or any oral anti-diabetic other than metformin, within 8 weeks
             prior to Visit 1

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2567</url>
    <description>Results for CLAF237A23119 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, Purkayastha D, Baron M. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009 Oct;11(10):978-86. doi: 10.1111/j.1463-1326.2009.01080.x. Epub 2009 Jul 13.</citation>
    <PMID>19614942</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>vildagliptin</keyword>
  <keyword>hemoglobin A1c</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

